PSA mass as a marker of prostate cancer progression after radical prostatectomy

Medical Science Monitor

Volumn 17, Issue 2, 2011, Pages

  Bryniarski, Piotr ^a   Paradysz, Andrzej ^a   Fryczkowski, Mieczysław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Hemodilution; Obesity; Prostate cancer; PSA mass; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FATALITY; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY;

EID: 79551710398     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881395     Document Type: Article

References (18)

1. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 1999; 17: 1499-507
2. Kattan MW, Eastham JA, Stapleton AMF et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 1998; 90: 766-71
3. Bañez LL, Hamilton RJ, Partin AW et al: Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA, 2007; 298: 2275-80
4. Vollmer RT, Humphrey PA: Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic viewpoint. Am J Clin Pathol, 2003; 119: 80-89
5. Boer P: Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol, 1984; 247: 632-36
6. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med, 1916; 17: 863-71
7. Spangler E, Zeigler-Johnson CM, Coomes M et al: Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol, 2007; 178: 1939-44
8. Bray GA: Obesity: the disease. J Med Chem, 2006; 49: 4001-7
9. Hsing AW, Reichardt JK, Stanczyk FZ: Hormones and prostate cancer: current perspectives and future directions. Prostate, 2002; 52: 213-35
10. Kaaks R, Lukanova A, Sommersberg B: Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis, 2000; 3: 157-72
11. Gong Z, Agalliu I, Lin DW et al: Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer, 2007; 109: 1192-202
12. Benez LL, Hamilton RJ, Vollmer RT et al: Can hemodilution explain the lower PSA concentrations among obese men? J Urol, 2007; 177(Supl.4): abs.4, 1418
13. Rodriguez C, Patel AV, Calle EE et al: Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev, 2001; 10: 345-53
14. Werny DM, Thompson T, Saraiya M et al: Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev, 2007; 16: 70-76
15. Baillargeon J, Pollock BH, Kristal AR et al: The association of body mass index and prostate-specific antigen in a population-based study. Cancer, 2005; 103: 1092-95
16. Freedland SJ, Platz EA, Presti JC Jr et al: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol, 2006; 175: 500-4
17. Saraiya M, Kottiri BJ, Leadbetter S et al: Total and percent free prostatespecific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev, 2005; 14: 2178-82
18. Xu J, Meyers DA, Sterling DA et al: Association studies of serum prostate- specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev, 2002; 11: 664-69